PMID- 33591944
OWN - NLM
STAT- MEDLINE
DCOM- 20210723
LR  - 20210723
IS  - 1945-4589 (Electronic)
IS  - 1945-4589 (Linking)
VI  - 13
IP  - 4
DP  - 2021 Feb 11
TI  - Identification of novel candidate biomarkers for pancreatic adenocarcinoma based 
      on TCGA cohort.
PG  - 5698-5717
LID - 10.18632/aging.202494 [doi]
AB  - Pancreatic adenocarcinoma (PAAD) is the most serious solid tumor type throughout 
      the world. The present study aimed to identify novel biomarkers and potential 
      efficacious small drugs in PAAD using integrated bioinformatics analyses. A total 
      of 4777 differentially expressed genes (DEGs) were filtered, 2536 upregulated 
      DEGs and 2241 downregulated DEGs. Weighted gene co-expression network analysis 
      was then used and identified 12 modules, of which, blue module with the most 
      significant enrichment result was selected. KEGG and GO enrichment analyses 
      showed that all DEGs of blue module were enriched in EMT and PI3K/Akt pathway. 
      Three hub genes (ITGB1, ITGB5, and OSMR) were determined as key genes with higher 
      expression levels, significant prognostic value and excellent diagnostic 
      efficiency for PAAD. Additionally, some small molecule drugs that possess the 
      potential to treat PAAD were screened out, including thapsigargin (TG). 
      Functional in vitro experiments revealed that TG repressed cell viability via 
      inactivating the PI3K/Akt pathway in PAAD cells. Totally, our findings identified 
      three key genes implicated in PAAD and screened out several potential small drugs 
      to treat PAAD.
FAU - Jie, Yang
AU  - Jie Y
AD  - Department of Pharmacy, Shandong Provincial Hospital, Jinan 250022, Shandong, 
      P.R. China.
FAU - Peng, Wang
AU  - Peng W
AD  - Department of Pharmacy, The First Affiliated Hospital of Shandong First Medical 
      University, Jinan 250014, Shandong, P.R. China.
FAU - Li, Yuan-Yuan
AU  - Li YY
AD  - Department of Pharmacy, The First Affiliated Hospital of Shandong First Medical 
      University, Jinan 250014, Shandong, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20210211
PL  - United States
TA  - Aging (Albany NY)
JT  - Aging
JID - 101508617
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (ITGB5 protein, human)
RN  - 0 (Integrin beta Chains)
RN  - 0 (Integrin beta1)
RN  - 0 (Itgb1 protein, human)
RN  - 0 (MIRN16 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 67526-95-8 (Thapsigargin)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Adenocarcinoma/drug therapy/*metabolism
MH  - Biomarkers, Tumor/*metabolism
MH  - Case-Control Studies
MH  - Cell Line, Tumor
MH  - Drug Screening Assays, Antitumor
MH  - Gene Regulatory Networks
MH  - Humans
MH  - Integrin beta Chains/metabolism
MH  - Integrin beta1/metabolism
MH  - MicroRNAs/metabolism
MH  - Pancreatic Neoplasms/drug therapy/*metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Thapsigargin/pharmacology/therapeutic use
PMC - PMC7950294
OTO - NOTNLM
OT  - biomarker
OT  - connectivity map (CMap)
OT  - pancreatic adenocarcinoma (PAAD)
OT  - small molecule drug
OT  - weighted co-expression network analysis (WGCNA)
COIS- CONFLICTS OF INTEREST: The authors declare that they have no conflicts of 
      interest.
EDAT- 2021/02/17 06:00
MHDA- 2021/07/24 06:00
PMCR- 2021/02/28
CRDT- 2021/02/16 17:10
PHST- 2020/07/02 00:00 [received]
PHST- 2020/12/18 00:00 [accepted]
PHST- 2021/02/17 06:00 [pubmed]
PHST- 2021/07/24 06:00 [medline]
PHST- 2021/02/16 17:10 [entrez]
PHST- 2021/02/28 00:00 [pmc-release]
AID - 202494 [pii]
AID - 10.18632/aging.202494 [doi]
PST - ppublish
SO  - Aging (Albany NY). 2021 Feb 11;13(4):5698-5717. doi: 10.18632/aging.202494. Epub 
      2021 Feb 11.